Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis
Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.1212313/full
Background: According to the 2023 guidelines for treating non-small-cell lung cancer (NSCLC), first-line treatment and recently developed agents for the treatment of epidermal growth factor (EGFR) mutation-positive locally advanced or...
Conclusion: Based on these analyses of survival benefits, tumor burden response, and safety, furmonertinib (Fur), Osi, and aumolertinib (Aum) may represent the best treatment regimen options for Asian patients, significantly prolonging survival (as measured by median PFS/OS), eliciting a greater tumor burden response, and exposing patients to...
A Case of Pathologically Complete Response After Nivolumab Combined with Chemotherapy in a Gastric Cancer Patient with Virchow's Lymph Node Metastasis
Describing a rare case of initially unresectable gastric cancer treated with nivolumab combined chemotherapy, achieving a pathologically complete response
Conclusion: The present study reports a rare case of initially unresectable gastric cancer with Virchow’s LNM showing a pathologically complete response to pre-operative chemotherapy combined with ICI. A treatment strategy that evaluates distant metastasis, aiding in the decision on whether to perform curative conversion surgery, may be...
The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma - Journal of Experimental & Clinical Cancer Research
Source : https://jeccr.biomedcentral.com/articles/10.1186/s13046-023-02615-2
Background Advanced gastric cancer (GC) is a lethal malignancy, harboring recurrent alterations in cell cycle pathway, especially the CDKN2A-CDK4/CDK6/CCND1 axis. However, monotherapy of CDK4/6 inhibitors has shown limited antitumor effects...
Conclusion: This study thus proposes a candidate combination therapy of ABE and JQ1 to improve the therapeutic efficacy and worth further investigation in clinical trials for GC.
p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer
Source : https://www.sciencedirect.com/science/article/abs/pii/S0006295220305566?via=ihub
Cell cycle control is often disrupted in gastric cancer (GC), making it an attractive therapeutic target. Abemaciclib is a specific CDK4/6 inhibitor t...
Conclusions/Relevance: Collectively, these data provide a foundation for clinical trials to assess the therapeutic efficacy of abemaciclib in GC and suggest that p16 methylation could be used as a predictive marker to identify patients with GC who may benefit from abemaciclib-based therapies.
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/30344100/
Gastric cancer displays marked molecular heterogeneity with aggressive behavior and treatment resistance. Therefore, good in vitro models that encompass unique subtypes are urgently needed for precision medicine development. Here, we...
Relevance: Overall, this new GCO biobank, with linked genomic data, provides a useful resource for studying both cancer cell biology and precision cancer therapy.